Apogee Therapeutics, INC Form 4 insider transactions

Director Nimish Shah of Apogee Therapeutics acquired stock options for 10,370 shares of common stock on June 5, 2024, according to a recent SEC filing.

Andrew Gottesdiener, a director at Apogee Therapeutics, acquired stock options for 10,370 shares of common stock on June 5, 2024.

Fairmount Funds Management LLC, along with Tomas Kiselak and Peter Harwin, reported the acquisition of stock options in Apogee Therapeutics, Inc.

Director Lisa Bollinger reports the acquisition of stock options for 18,550 shares of Apogee Therapeutics common stock.

Fairmount Funds Management LLC reports the transfer of Apogee Therapeutics shares from Fairmount Healthcare Fund LP to Fairmount Healthcare Fund II LP as part of a fund wind down.